ORCHPHARMA

Orchid Pharma Share Price

 

 

Invest in Orchid Pharma with 2.19X leverage

Invest with MTF

Performance

  • Low
  • ₹726
  • High
  • ₹755
  • 52 Week Low
  • ₹604
  • 52 Week High
  • ₹1,910
  • Open Price₹753
  • Previous Close₹757
  • Volume24,017
  • 50 DMA₹791.22
  • 100 DMA₹789.83
  • 200 DMA₹838.76

Investment Returns

  • Over 1 Month -12.56%
  • Over 3 Month -2.29%
  • Over 6 Month + 0.77%
  • Over 1 Year -60.51%

Smart Investing Starts Here Start SIP with Orchid Pharma for Steady Growth!

Invest Now

Orchid Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 70.7
  • PEG Ratio
  • -1.3
  • Market Cap Cr
  • 3,695
  • P/B Ratio
  • 2.9
  • Average True Range
  • 26.6
  • EPS
  • 10.3
  • Dividend Yield
  • 0
  • MACD Signal
  • -12.4
  • RSI
  • 32
  • MFI
  • 21.46

Orchid Pharma Financials

Orchid Pharma Technicals

EMA & SMA

Current Price
₹728.50
-28.55 (-3.77%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹782.71
  • 50 Day
  • ₹791.22
  • 100 Day
  • ₹789.83
  • 200 Day
  • ₹838.76

Resistance and Support

736.5 Pivot Speed
  • R3 776.00
  • R2 765.50
  • R1 747.00
  • S1 718.00
  • S2 707.50
  • S3 689.00

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Orchid Pharma is a leading pharmaceutical company in India, specializing in the manufacture of active pharmaceutical ingredients (APIs) and generic formulations. It serves global markets with a focus on antibiotics, anti-inflammatory, and central nervous system therapies.

Orchid Pharma has an operating revenue of Rs. 821.27 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 10% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 9 which is a POOR score indicating inconsistency in earnings, a RS Rating of 48 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 69 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Orchid Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-11 Quarterly Results
2025-08-12 Quarterly Results
2025-05-26 Audited Results
2025-02-12 Quarterly Results
2024-11-11 Quarterly Results

Orchid Pharma F&O

Orchid Pharma Shareholding Pattern

69.84%
18.04%
0.14%
1.56%
0.06%
7.03%
3.33%

About Orchid Pharma

  • NSE Symbol
  • ORCHPHARMA
  • BSE Symbol
  • 524372
  • Managing Director
  • Mr. Manish Dhanuka
  • ISIN
  • INE191A01027

Similar Stocks to Orchid Pharma

Orchid Pharma FAQs

Orchid Pharma share price is ₹728 As on 12 January, 2026 | 01:41

The Market Cap of Orchid Pharma is ₹3694.9 Cr As on 12 January, 2026 | 01:41

The P/E ratio of Orchid Pharma is 70.7 As on 12 January, 2026 | 01:41

The PB ratio of Orchid Pharma is 2.9 As on 12 January, 2026 | 01:41

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23